Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Injection in Advanced NSCLC After ≥2 Prior Therapies
CTR20200401Phase 2Active
- Sponsor
- Biostar Pharmaceuticals
- Start
- Mar 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in non-small cell lung cancer (NSCLC), sponsored by Biostar Pharmaceuticals. Started Mar 2020; status: active.
02
Drugs
utidelone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200401.